

汉 光 国 际

感 染 性 疾 病 研 究 中 心

Katharine Hsu International Research Center  
of Human Infectious Diseases



# New Tools to Manage an Old Disease – Genotyping and QuantiFERON

Edward A. Graviss, Ph.D., MPH  
Baylor College of Medicine

# Genotyping - Definition

- The molecular characterization and utilization of nucleic acid regions or elements within *M. tuberculosis* genome for identification purposes.
- AKA - Fingerprinting


# Nucleic Acid – Based Genotyping Methods

- 1) Restriction Fragment Length Polymorphism (RFLP) analysis
  - Utilize well-characterized repetitive element Insertion Sequence 6110 (*IS6110*)
  - Standardized methodology - van Embden
  - Computerized laboratory database


# Nucleic Acid – Based Genotyping Methods <sup>(2)</sup>

- 2) Spoligotyping - Spacer oligonucleotide typing
- PCR method exploiting DNA polymorphisms within the direct repeat (DR) locus of MTB
  - Locus contains multiple, well-conserved 36 bp DRs interspersed with non-repetitive spacer sequences 34-41 bp long
  - Variation in the 43 spacers reflects the polymorphisms studied

# Spoligotyping Schematic



# Spoligotyping Schematic



# Spoligotyping Advantages

a) Smaller amounts of DNA needed, so procedure can be run on clinical samples or on strains shortly after liquid inoculation

b) Results expressed in digital format –

7777 7677 7760 771    Print 4

7777 7747 7760 631    H37Rv




# Nucleic Acid – Based Genotyping Methods <sup>(3)</sup>

## 3) MIRU-VNTR

- PCR method characterizing number and size of variable number of tandem repeats in each of 12 independent mycobacterial interspersed repetitive units
- Appropriate for all MTB strains no matter the IS6110 number
- Rapid comparison of results (12 digit classification system)

# MIRU-VNTR Schematic



# Genotyping Assumptions

- Epidemiologically related strains will have the same genotype pattern and unrelated strains will have different patterns.
  - Same patterns = cluster = ongoing transmission
  - Different patterns = unique, non-clustered = reactivation or LTBI

# Lessons Learned <sup>(1)</sup>

- Infectiousness of patients – “bar-hoppers”
- Recurrent and exogenous reinfection - In Houston relapse of new strain (24-31%)
- Impact of drug resistance on transmission – drug-resistant strains less likely to be clustered

# Lessons Learned <sup>(2)</sup>

- Contact and outbreak investigations – transmission can occur through short-term, casual contact; ineffective contact tracing
- Measure the performance of TB control programs – proportion of cases that are clustered
- Geographic distribution and dissemination of MTB – 25% of clustered isolates in Houston are Beijing-family strains



# QuantiFERON



# QuantiFERON

- Until recently, the TST was the only method available for diagnosis of LTBI
- Utility of TST hampered by:
  - Potential for false positive and false negative results
  - Administration and interpretation
  - Difficulty in separating true infection from the effects of prior BCG vaccination
  - Infections caused by non-tuberculosis mycobacterium (NTM)

# QuantiFERON

- Advances in genomics and immunology have led to a promising alternative – *in vitro* interferon-gamma (INF  ) assays
- **Principle** – T-cells of individuals infected with *M. tuberculosis* release INF  when they re-encounter TB-specific antigens.



# QuantiFERON Antigens

- QuantiFERON (first generation) – Similar to PPD at least 100 different mycobacterial antigens
- QuantiFERON – Gold (second generation, 2G) – Use two mycobacterial specific antigens: early secreted antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP10)
- QuantiFERON – Gold *In Tube* ( third generation, 3G) – ESAT-6; CFP10; and TB7.7 (Rv2654)

# Advantages of INF Assays

- Higher specificity – less influence by BCG vaccination
- At least as sensitive as TST in active TB
- Need for fewer patient visits
- Avoid subjective readings
- Ability to perform serial testing without boosting

# Limitations of QuantiFERON

- Higher costs -
  - TST = \$ 9.79 (Center for Medical Services, CPT 86580)
  - QFT-Gold = \$37.39 (BMC Infectious Diseases 2006, 6:47)
- Need for laboratory support –
  - Courier to laboratory for processing on the same day as phlebotomy (12 hour window)
- Need for venous blood –
  - Heparinized whole-blood assay

# Limitations of QuantiFERON

- Package Insert – “Gold not evaluated for use in”
  - Immunosuppressed
  - < 17 years of age
  - Pregnant women
- Lack of published data

# Stage 1 (QuantiFERON – Gold)

- Aliquot 1ml of heparinized whole blood into 4 wells of a 24/96-well culture plate
- Add 3 drops of antigens/controls

**FIGURE 1. Recommended layout for dispensing Blood and Stimulation Antigens into 24 Well Culture Plates**

	Patient Sample Number					
	1	2	3	4	5	6
<b>Nil Control</b> ( <i>gray cap</i> )	○	○	○	○	○	○
<b>ESAT-6</b> ( <i>red cap</i> )	○	○	○	○	○	○
<b>CFP-10</b> ( <i>white cap</i> )	○	○	○	○	○	○
<b>Mitogen</b> ( <i>purple cap</i> )	○	○	○	○	○	○


# Stage 1 - continued

- Shake covered plate for 1-2 minutes
- Incubate at 37°C (humidified) for 16-24 hours
- Harvest  $\geq$  200ml plasma from each well
- Store plasma in racked microtubes or uncoated microtitre plate:

2 – 8°C	< 28 days
-20°C	Up to 3 months

# Stage 2 and Standard Preparation

- Add 50ml of conjugate solution to each well
- Add 50ml plasma/standard to the appropriate wells



# 96-well format

**FIGURE 2. Recommended Sample Layout - Whole Plate**


Row	1	2	3	4	5	6	7	8	9	10	11	12
A	1N	2N	3N	4N	5N	S1	S1	6N	7N	8N	9N	10N
B	1E	2E	3E	4E	5E	S2	S2	6E	7E	8E	9E	10E
C	1C	2C	3C	4C	5C	S3	S3	6C	7C	8C	9C	10C
D	1M	2M	3M	4M	5M	S4	S4	6M	7M	8M	9M	10M
E	11N	12N	13N	14N	15N	S5	S5	16N	17N	18N	19N	20N
F	11E	12E	13E	14E	15E	S6	S6	16E	17E	18E	19E	20E
G	11C	12C	13C	14C	15C	S7	S7	16C	17C	18C	19C	20C
H	11M	12M	13M	14M	15M	S8	S8	16M	17M	18M	19M	20M

*S1–8 (S1: Standard 1, S2: Standard 2, S3: Standard 3, S4: Standard 4, S5: Standard 5, S6: Standard 6, S7: Standard 7, S8: Standard 8); 1N (Sample 1 Nil Control plasma); 1E (Sample 1 ESAT-6 plasma); 1C (Sample 1 CFP-10 plasma); 1M (Sample 1 Mitogen Control plasma)*



# Stage 2 - continued

- Shake covered plate for 1 minute
- Incubate at room temperature for 2 hours
- Wash plate  $\geq 6$  times
- Add 100ml of substrate
- Incubate for 30 minutes at room temperature
- Add 100ml of stop solution
- Read absorbance at 450nm within 5 mins



Measure OD and  
determine IFN- $\gamma$  levels

# Results Interpretation

Mitogen-Nil <sup>1</sup> IU/mL	ESAT-6 - Nil AND/OR CFP-10 - Nil IU/mL	Report	Interpretation
≥ 0.5	≥ 0.35	QuantiFERON®-TB Gold Positive	<i>M. tuberculosis</i> infection likely
< 0.5	≥ 0.35	QuantiFERON®-TB Gold Positive	<i>M. tuberculosis</i> infection likely
≥ 0.5	< 0.35	QuantiFERON®-TB Gold Negative	<i>M. tuberculosis</i> infection NOT likely
< 0.5	< 0.35	QuantiFERON®-TB Gold Indeterminate	<i>Result not obtained</i>

<sup>1</sup> Mitogen - Nil must be ≥ 0.5 IU/mL OR either ESAT-6 or CFP-10 minus Nil must be ≥ 0.35 IU/mL for a subject to have a valid QuantiFERON®-TB Gold result.

<sup>2</sup> For a patient to be considered POSITIVE for *M. tuberculosis* infection, either or both of the individual CFP-10 minus Nil and ESAT-6 minus Nil responses must be greater than or equal to 0.35 IU/mL.

# QuantiFERON - Gold vs TST

Korean med students:  $n = 99$  (54 pulm TB+)

specificity = 96% vs 49%

sensitivity = 81% vs 78%

Italian unselected hospital pts:  $n = 318$

sensitivity = 67% vs 33%

large number of indeterminants ( $n = 50$ )

# Where do we go from here?

## Genotyping –

Better nucleic acid and genotypic markers needed;

Complete laboratory-based surveillance, will need legislation to coax labs into submitting isolates to a central location.

Use for program evaluation – (gold standard)?

# Where do we go from here?

## QuantiFERON –

Additional labs in Texas need to begin using IFG 📞 on a routine basis.

Large well-planned, head-on-head INF 📞 studies needed.

Additional studies on feasibility, acceptability and cost-benefit of INF 📞 assays needed

# Big Thanks!

